Bulk Inquiry
Capmatinib
- INC280 - INCB28060
- Soluble in DMSO
- MF: C23H17FN6O
- MW: 412.42
Description
Capmatinib is a highly potent, selective, ATP competitive and orally bioavailable c-MET inhibitor with an IC50 value of 0.13 nM.
More Information
| Parent CAS No. | 1029712-80-8 |
|---|---|
| Chemical Name | 2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide |
| SMILES | C1(C2C=CC(C(=O)NC)=C(F)C=2)=NN2C(CC3C=CC4N=CC=CC=4C=3)=CN=C2N=C1 |
| MFCD | N.A. |
| InChi | InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31) |
| InChiKey | LIOLIMKSCNQPLV-UHFFFAOYSA-N |
| CID | 25145656 |
| Short Description | MET inhibitor |
References
- K Moran-Jones et al. INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models. Sci Rep. 2015 Jul 3;5:11749.
- X Liu et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011 Nov 15;17(22):7127-38.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1581 | SU 11274 |
From $99.00 |
| 1582 | Foretinib |
From $99.00 |
| 1583 | PF 04217903 mesylate |
From $88.00 |
| 1660 | Crizotinib |
From $88.00 |
| 1819 | Cabozantinib S-malate |
From $66.00 |
| 1838 | ARQ 197 |
From $99.00 |
| 1914 | SGX 523 |
From $132.00 |
| 1916 | AMG 208 |
From $104.50 |
| 1959 | Golvatinib |
From $99.00 |
| 2368 | Amuvatinib |
From $132.00 |
| 2553 | LY 2801653 |
From $132.00 |
| 3864 | Volitinib dihydrochloride |
From Inquiry |
| 3945 | AMG-337 |
From Inquiry |
| 3946 | Altiratinib |
From Inquiry |
| 3975 | MGCD265 dihydrochloride |
From $143.00 |
| 4040 | BMS-777607 |
From Inquiry |
| 4266 | BPI-9016M |
From Inquiry |
